Javier Munoz, MD, MS, FACP
Therapeutic options for patients with mantle cell lymphoma (MCL) now include the novel Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa). On November 14, 2019, the FDA granted accelerated approval to zanubrutinib for adult patients with MCL who have received ≥1 prior treatment. The approval for the rare and aggressive subtype of B-cell non-Hodgkin lymphoma was handed down 3 months ahead of the planned action date based on the overall response rates (ORRs) observed in 2 single-arm trials.
... to read the full story